Alterity Therapeutics Limited Files Form 6-K: February 2025 Insights

Here are the key insights extracted from the provided section of the financial report:

1. Report Type and Filing: This document is a Form 6-K, which is filed by foreign private issuers to disclose certain information to the SEC. It is specifically submitted under Rule 13a-16 or 15d-163 of the Securities Exchange Act of 1934.
2. Reporting Period: The report covers the month of February 2025.
3. Company Information:

• Name: Alterity Therapeutics Limited
• Nature: The company is identified as a development stage enterprise.
• Address: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.

4. Annual Reports Filing: The registrant is indicating its filing method for annual reports:

• The registrant has checked the box for Form 20-F and left the box for Form 40-F unchecked. This suggests that the company will file its annual report using Form 20-F, which is typically used by foreign companies.

5. Incorporation of Documents: This Form 6-K includes information that will be incorporated by reference into its Registration Statement on Form S-8 and several Form F-3 Registration Statements. The specific Registration Statements referenced are:

• Form S-8: 333-251073, 333-248980, 333-228671.
• Form F-3: 333-274816, 333-251647, 333-231417, 333-250076.

6. Exhibits Submitted: The report mentions the submission of an exhibit:

• Exhibit 99.1: Application for quotation of securities - ATH.

7. Signature: The report is signed by Geoffrey P. Kempler, who holds the title of Chairman of Alterity Therapeutics Limited. The signature indicates that the filing is authorized at the executive level.
8. Date of Signing: The report was signed on February 18, 2025.

These points summarize the essential details and implications of the filing, particularly concerning the company's reporting obligations and its registration status with the SEC.